

Ontario Public Drug Programs

Drug Submission Status

Generic Name: eribulin mesylate

Brand Name: Halaven

Strength: 0.5 mg/mL IV solution

Manufacturer: Eisai Limited

Indication: For metastatic breast cancer in patients who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease

Rapid Review: Not requested

Submission Type:	Date Submission Received:	Date Submission Deemed Complete:	Review Status:	Funding Decision:
First Review (Initial Submission)	24/04/2012	30/05/2012	EO decision rendered	Funding not considered through Cancer Care Ontario's New Drug Funding Program

Rapid Review:

Details of the Rapid Review process can be found at:

www.health.gov.on.ca/english/providers/program/drugs/drug_submissions/rapid_review_process.html

Review Status:

- Screening – Ministry is screening the manufacturer's submission to ensure all regulatory and policy requirements have been met in order to proceed with the drug review.
- Submission incomplete – Manufacturer did not meet the necessary requirements to allow review to proceed.
- Submission complete & under review – Manufacturer met all requirements to proceed with the drug review, and evaluation of the drug submission is underway.
- Committee to Evaluate Drugs (CED) review completed, manufacturer requesting reconsideration – A recommendation was made by the CED, however the manufacturer has submitted or will be submitting additional information.
- Committee to Evaluate Drugs (CED) review completed – A recommendation was made by the CED.
- Executive Officer (EO) decision rendered.

Funding Status:

The Committee to Evaluate Drugs (CED) recommendation and the Executive Officer (EO) decision, if available, can be found at: www.health.gov.on.ca/english/providers/program/drugs/ced_rec_table.html

Updated: January 17, 2013